White Plains Hospital is the only Hospital in Westchester County, and one of only eight in New York state, to receive five stars. To learn more and see how White Plains Hospital compares to other hospitals in the region, visit: https://www.medicare.gov/care-compare/
The CMS ratings are based on more than 40 quality measurements that fall into five categories: mortality, safety of care, readmissions after treatment of common conditions, patient experience, and timely and effective care.
Regeneron Genetics Center Discovers Rare Mutations In The CIDEB Gene That Protect Against Liver Disease
Tarrytown headquartered Regeneron Pharmaceuticals, Inc. announced that scientists from the Regeneron Genetics Center® (RGC) have uncovered rare genetic loss-of-function mutations in the CIDEB gene that are associated with substantial protection from liver disease, including serious diseases such as nonalcoholic steatohepatitis (NASH) and cirrhosis. The new discovery has been published in The New England Journal of Medicine.
Oligomerix Announces Key Organizational Changes in Transition to Clinically Focused Company
Oligomerix will now operate as two distinct business units: Discovery Group and Development Group, which will include both clinical and commercial development activities. As part of this reorganization, Dr. William Erhardt, M.D., previously chief medical officer of Oligomerix, will become president and head of development and operations.
Dr. Erhardt’s primary focus will be to lead the organization into the clinic and take on all the obligations and responsibilities of that task for the entire organization. Dr. James Moe will remain CEO and will assume the new responsibility of leading the Discovery Group as head of research and strategy, working in collaboration with Chief Scientific Officer Dr. Eliot Davidowitz. Additionally, Chief Financial Officer Robert Foerster will assume the additional role of chief operating officer.
Cognition Therapeutics Presenting New Analyses from Ongoing Clinical Trial of CT1812 in Mild-to-Moderate Alzheimer’s Disease
CT1812 is an oral, small molecule that selectively binds to the sigma-2 (σ-2) receptor complex. Evidence implicates σ-2 receptors in the regulation of key cellular processes that are damaged in Alzheimer’s disease, dementia with Lewy bodies (DLB) and other neurodegenerative disorders.
